Huaren Pharmaceutical Co., Ltd. agreed to acquire Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke Pharmaceutical Packaging Co., Ltd. from Ruan Chuanming, Ruan Yingle and He Hui for approximately CNY 390 million.
November 05, 2020
Share
Huaren Pharmaceutical Co., Ltd. (SZSE:300110) agreed to acquire Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke Pharmaceutical Packaging Co., Ltd. from Ruan Chuanming, Ruan Yingle and He Hui for approximately CNY 390 million on June 23, 2020. An equity transfer agreement was signed on October 26, 2020. The twentieth (temporary) meeting of the sixth Board of Directors of Huaren Pharmaceutical approved the transaction.
Huaren Pharmaceutical CO.,LTD is a China-based company principally engaged in the research, development, manufacture and distribution of non polyvinyl chloride (PVC) soft bag large volume preparations. The Company provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The Company distributes its products in domestic market, with Northeast China as its main market.
Huaren Pharmaceutical Co., Ltd. agreed to acquire Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke Pharmaceutical Packaging Co., Ltd. from Ruan Chuanming, Ruan Yingle and He Hui for approximately CNY 390 million.
HUAREN PHARMACEUTICAL CO., LTD. 
